247 related articles for article (PubMed ID: 33876951)
61. Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells.
Patsali P; Turchiano G; Papasavva P; Romito M; Loucari CC; Stephanou C; Christou S; Sitarou M; Mussolino C; Cornu TI; Antoniou MN; Lederer CW; Cathomen T; Kleanthous M
Haematologica; 2019 Nov; 104(11):e497-e501. PubMed ID: 31004018
[No Abstract] [Full Text] [Related]
62. Engineering of the endogenous
Boontanrart MY; Mächler E; Ponta S; Nelis JC; Preiano VG; Corn JE
Elife; 2023 Jun; 12():. PubMed ID: 37265399
[TBL] [Abstract][Full Text] [Related]
63. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
[TBL] [Abstract][Full Text] [Related]
64. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
65. 3'HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression.
Himadewi P; Wang XQD; Feng F; Gore H; Liu Y; Yu L; Kurita R; Nakamura Y; Pfeifer GP; Liu J; Zhang X
Elife; 2021 Sep; 10():. PubMed ID: 34585664
[TBL] [Abstract][Full Text] [Related]
66. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
Segura EER; Ayoub PG; Hart KL; Kohn DB
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
[TBL] [Abstract][Full Text] [Related]
67. Gene Therapy for beta-thalassemia.
Malik P; Arumugam PI
Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
[TBL] [Abstract][Full Text] [Related]
68. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
Hoban MD; Lumaquin D; Kuo CY; Romero Z; Long J; Ho M; Young CS; Mojadidi M; Fitz-Gibbon S; Cooper AR; Lill GR; Urbinati F; Campo-Fernandez B; Bjurstrom CF; Pellegrini M; Hollis RP; Kohn DB
Mol Ther; 2016 Sep; 24(9):1561-9. PubMed ID: 27406980
[TBL] [Abstract][Full Text] [Related]
69. Fessas P, Stamatoyannopoulos G. Hereditary persistence of fetal hemoglobin in Greece: a study and a comparison. Blood. 1964;24(3):223-240.
Blood; 2016 Jul; 128(1):5. PubMed ID: 27389537
[No Abstract] [Full Text] [Related]
70. Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies.
Wang L; Li L; Ma Y; Hu H; Li Q; Yang Y; Liu W; Yin S; Li W; Fu B; Kurita R; Nakamura Y; Liu M; Lai Y; Li D
Cell Res; 2020 Mar; 30(3):276-278. PubMed ID: 31911671
[No Abstract] [Full Text] [Related]
71. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.
Cromer MK; Camarena J; Martin RM; Lesch BJ; Vakulskas CA; Bode NM; Kurgan G; Collingwood MA; Rettig GR; Behlke MA; Lemgart VT; Zhang Y; Goyal A; Zhao F; Ponce E; Srifa W; Bak RO; Uchida N; Majeti R; Sheehan VA; Tisdale JF; Dever DP; Porteus MH
Nat Med; 2021 Apr; 27(4):677-687. PubMed ID: 33737751
[TBL] [Abstract][Full Text] [Related]
72.
Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
[TBL] [Abstract][Full Text] [Related]
73. Generation of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system.
Ajami M; Atashi A; Kaviani S; Kiani J; Soleimani M
J Cell Biochem; 2020 Feb; 121(2):1420-1430. PubMed ID: 31596028
[TBL] [Abstract][Full Text] [Related]
74. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.
Thuret I; Ruggeri A; Angelucci E; Chabannon C
Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028
[TBL] [Abstract][Full Text] [Related]
75. Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.
Ghiaccio V; Chappell M; Rivella S; Breda L
Mol Diagn Ther; 2019 Apr; 23(2):173-186. PubMed ID: 30701409
[TBL] [Abstract][Full Text] [Related]
76. Rapid and Sensitive Assessment of Globin Chains for Gene and Cell Therapy of Hemoglobinopathies.
Loucari CC; Patsali P; van Dijk TB; Stephanou C; Papasavva P; Zanti M; Kurita R; Nakamura Y; Christou S; Sitarou M; Philipsen S; Lederer CW; Kleanthous M
Hum Gene Ther Methods; 2018 Feb; 29(1):60-74. PubMed ID: 29325430
[TBL] [Abstract][Full Text] [Related]
77. Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression.
Antoniou P; Hardouin G; Martinucci P; Frati G; Felix T; Chalumeau A; Fontana L; Martin J; Masson C; Brusson M; Maule G; Rosello M; Giovannangeli C; Abramowski V; de Villartay JP; Concordet JP; Del Bene F; El Nemer W; Amendola M; Cavazzana M; Cereseto A; Romano O; Miccio A
Nat Commun; 2022 Nov; 13(1):6618. PubMed ID: 36333351
[TBL] [Abstract][Full Text] [Related]
78. Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.
Breda L; Rivella S; Zuccato C; Gambari R
Expert Rev Hematol; 2013 Jun; 6(3):255-64. PubMed ID: 23782080
[TBL] [Abstract][Full Text] [Related]
79. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
[TBL] [Abstract][Full Text] [Related]
80. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
Bao LW; Zhou YY; Zeng FY
Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
